Compare Stocks: MBOT, CLPT, NPCE, and DCTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$14.57 +2.5%	$15.57	$8.27 ▼ $30.10	$444.39M	1.24	742,273 shs	422,272 shs
DCTH Delcath Systems	$16.67 +10.3%	$12.35	$8.12 ▼ $16.69	$578.45M	0.52	479,645 shs	1.48 million shs
MBOT Microbot Medical	$1.94 +2.4%	$1.83	$1.60 ▼ $4.67	$129.97M	1.06	1.53 million shs	619,928 shs
NPCE NeuroPace	$14.88 +0.3%	$15.62	$7.56 ▼ $19.60	$507.26M	1.92	205,631 shs	234,544 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	0.00%	-4.89%	-18.80%	+15.43%	+31.33%
DCTH Delcath Systems	0.00%	+23.65%	+16.14%	+36.62%	+50.95%
MBOT Microbot Medical	0.00%	+9.88%	0.00%	-13.70%	-38.83%
NPCE NeuroPace	0.00%	+15.05%	-13.33%	-5.36%	+65.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$14.57 +2.5%	$15.57	$8.27 ▼ $30.10	$444.39M	1.24	742,273 shs	422,272 shs
DCTH Delcath Systems	$16.67 +10.3%	$12.35	$8.12 ▼ $16.69	$578.45M	0.52	479,645 shs	1.48 million shs
MBOT Microbot Medical	$1.94 +2.4%	$1.83	$1.60 ▼ $4.67	$129.97M	1.06	1.53 million shs	619,928 shs
NPCE NeuroPace	$14.88 +0.3%	$15.62	$7.56 ▼ $19.60	$507.26M	1.92	205,631 shs	234,544 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	0.00%	-4.89%	-18.80%	+15.43%	+31.33%
DCTH Delcath Systems	0.00%	+23.65%	+16.14%	+36.62%	+50.95%
MBOT Microbot Medical	0.00%	+9.88%	0.00%	-13.70%	-38.83%
NPCE NeuroPace	0.00%	+15.05%	-13.33%	-5.36%	+65.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	2.33	Hold	$25.67	75.68% Upside
DCTH Delcath Systems	2.57	Moderate Buy	$23.17	41.13% Upside
MBOT Microbot Medical	3.00	Buy	$6.63	242.38% Upside
NPCE NeuroPace	2.80	Moderate Buy	$19.29	29.30% Upside

Current Analyst Ratings Breakdown

Latest MBOT, CLPT, NPCE, and DCTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	DCTH Delcath Systems	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00 ➝ $32.00
8/6/2026	DCTH Delcath Systems	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $21.00
8/4/2026	CLPT ClearPoint Neuro	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
8/4/2026	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$22.00
7/29/2026	NPCE NeuroPace	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/23/2026	NPCE NeuroPace	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
7/22/2026	MBOT Microbot Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CLPT ClearPoint Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	MBOT Microbot Medical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$36.97M	12.05	N/A	N/A	$0.99 per share	14.76
DCTH Delcath Systems	$85.23M	6.68	$0.06 per share	289.05	$3.15 per share	5.21
MBOT Microbot Medical	N/A	N/A	N/A	N/A	$1.15 per share	N/A
NPCE NeuroPace	$99.99M	5.09	N/A	N/A	$0.57 per share	26.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$25.54M	-$1.18	N/A	N/A	N/A	-81.76%	-188.09%	-40.88%	N/A
DCTH Delcath Systems	$2.70M	$0.01	1,643.04	N/A	N/A	0.56%	0.46%	0.42%	N/A
MBOT Microbot Medical	-$13.14M	-$0.26	N/A	N/A	N/A	N/A	-21.84%	-20.71%	8/11/2026 (Estimated)
NPCE NeuroPace	-$21.47M	-$0.65	N/A	N/A	N/A	-21.67%	-108.20%	-18.50%	8/11/2026 (Estimated)

Latest MBOT, CLPT, NPCE, and DCTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MBOT Microbot Medical	-$0.08	N/A	N/A	N/A	$0.33 million	N/A
8/11/2026	Q2 2026	NPCE NeuroPace	-$0.2179	N/A	N/A	N/A	$22.61 million	N/A
8/6/2026	Q2 2026	DCTH Delcath Systems	-$0.0891	$0.07	+$0.1591	$0.07	$26.25 million	$29.13 million
8/3/2026	Q2 2026	CLPT ClearPoint Neuro	-$0.2867	-$0.38	-$0.0933	-$0.38	$12.73 million	$10.88 million
5/13/2026	Q1 2026	CLPT ClearPoint Neuro	-$0.28	-$0.32	-$0.04	-$0.32	$11.97 million	$12.13 million
5/13/2026	Q1 2026	MBOT Microbot Medical	-$0.08	-$0.05	+$0.03	-$0.05	$0.30 million	$0.11 million
5/12/2026	Q1 2026	NPCE NeuroPace	-$0.19	-$0.13	+$0.06	-$0.20	$21.65 million	$22.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
MBOT Microbot Medical	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	4.66	4.74	3.89
DCTH Delcath Systems	N/A	9.83	8.95
MBOT Microbot Medical	0.01	22.59	21.93
NPCE NeuroPace	4.08	5.38	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
DCTH Delcath Systems	61.12%
MBOT Microbot Medical	16.30%
NPCE NeuroPace	78.83%

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.94%
DCTH Delcath Systems	19.36%
MBOT Microbot Medical	4.74%
NPCE NeuroPace	19.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	30.50 million	28.39 million	Optionable
DCTH Delcath Systems	60	34.70 million	27.98 million	Optionable
MBOT Microbot Medical	20	67.17 million	63.98 million	Optionable
NPCE NeuroPace	170	34.09 million	27.55 million	Optionable

MBOT, CLPT, NPCE, and DCTH Headlines

Recent News About These Companies

NeuroPace (NPCE) to Post Earnings on Tuesday

August 10 at 2:10 AM | americanbankingnews.com

NeuroPace (NPCE) Expected to Release Earnings on Tuesday

August 4, 2026 | marketbeat.com

NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 4, 2026 | marketbeat.com

NeuroPace (NASDAQ:NPCE) Earns Buy Rating from HC Wainwright

July 31, 2026 | americanbankingnews.com

NeuroPace drops as bid to expand label for RNS System denied in US

July 30, 2026 | msn.com

NeuroPace (NASDAQ:NPCE) Gains A Fresh Regulatory Catalyst

July 30, 2026 | kalkinemedia.comK

HC Wainwright Reaffirms Buy Rating for NeuroPace (NASDAQ:NPCE)

July 29, 2026 | marketbeat.com

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

July 29, 2026 | finance.yahoo.com

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

July 29, 2026 | seekingalpha.com

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data

July 28, 2026 | marketbeat.com

Orbimed Advisors LLC Decreases Holdings in NeuroPace, Inc. $NPCE

July 27, 2026 | marketbeat.com

NeuroPace, Inc. $NPCE Shares Acquired by First Light Asset Management LLC

July 27, 2026 | marketbeat.com

Mizuho Begins Coverage on NeuroPace (NASDAQ:NPCE)

July 23, 2026 | marketbeat.com

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

July 15, 2026 | zacks.com

NeuroPace (NASDAQ:NPCE) Shares Down 5.8% - What's Next?

July 14, 2026 | marketbeat.com

NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

June 27, 2026 | insidermonkey.com

NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

June 27, 2026 | finance.yahoo.com

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

June 15, 2026 | zacks.com

NeuroPace Stock Draws Focus As RNS Adoption Expands

June 11, 2026 | kalkinemedia.comK

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

June 11, 2026 | zacks.com

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

June 10, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MBOT, CLPT, NPCE, and DCTH Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$14.57 +0.36 (+2.53%)

As of 04:00 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Delcath Systems NASDAQ:DCTH

$16.67 +1.56 (+10.32%)

As of 04:00 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Microbot Medical NASDAQ:MBOT

$1.94 +0.05 (+2.38%)

As of 04:00 PM Eastern

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

NeuroPace NASDAQ:NPCE

$14.88 +0.05 (+0.34%)

As of 04:00 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MBOT, CLPT, NPCE, and DCTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MBOT, CLPT, NPCE, and DCTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MBOT, CLPT, NPCE, and DCTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MBOT, CLPT, NPCE, and DCTH Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

Delcath Systems NASDAQ:DCTH

Microbot Medical NASDAQ:MBOT

NeuroPace NASDAQ:NPCE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MBOT, CLPT, NPCE, and DCTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MBOT, CLPT, NPCE, and DCTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MBOT, CLPT, NPCE, and DCTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MBOT, CLPT, NPCE, and DCTH Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

Delcath Systems NASDAQ:DCTH

Microbot Medical NASDAQ:MBOT

NeuroPace NASDAQ:NPCE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools